ストックスクリーナーアプリを入手
0.3602
8.83%
-0.0349
アフターアワーズ：
.37
0.0098
+2.72%
前日終値:
$0.3951
開ける：
$0.4075
24時間の取引高:
1.27M
Relative Volume:
0.32
時価総額：
$66.91M
収益：
-
当期純損益:
$-16.76M
株価収益率:
-4.5025
EPS:
-0.08
ネットキャッシュフロー:
$-132.97M
1週間 パフォーマンス:
-20.63%
1か月 パフォーマンス:
-39.98%
6か月 パフォーマンス:
-45.37%
1年 パフォーマンス:
-64.34%
1日の値動き範囲:
$0.36
$0.4182
1週間の範囲:
$0.36
$0.4599
52週間の値動き範囲:
$0.2612
$1.60
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
XFOR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
0.3602 | 66.91M | 0 | -16.76M | -132.97M | -0.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
Layoff Tracker: CRISPR, Cytiva Laying Off Employees - BioSpace
How pharma CEO pay shifted for these 4 companies last year - PharmaVoice
Atria Wealth Solutions Inc. Buys New Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
President and CEO Polymeropoulos Mihael Hristos bought $47,600 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,361,730 units (SEC Form 4) - Quantisnow
ANI Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Yahoo Finance
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease - Quantisnow
Earnings call transcript: Xenon Pharmaceuticals Q4 2024 sees slight EPS beat - Investing.com
Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World
President and CEO Polymeropoulos Mihael Hristos bought $47,650 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,341,730 units (SEC Form 4) - Quantisnow
Popular lemonade recalled by FDA for cancer-linked chemical - New York Post
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - Business Wire
President and CEO Polymeropoulos Mihael Hristos bought $44,640 worth of shares (10,000 units at $4.46), increasing direct ownership by 0.43% to 2,331,730 units (SEC Form 4) - Quantisnow
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - Business Wire
SVP, CFO & Treasurer Moran Kevin Patrick bought $8,779 worth of shares (2,000 units at $4.39), increasing direct ownership by 0.57% to 355,763 units (SEC Form 4) - Quantisnow
3 Pharmaceutical Stocks With Blockbuster Drug Potential - TradingView
Licensing For Innovation: A Decade Of Pharma Product Deals - Insights
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 - Business Wire
DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD) - PR Newswire
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" - Morningstar
SVP, CFO & Treasurer Moran Kevin Patrick was granted 125,000 shares, increasing direct ownership by 55% to 353,763 units (SEC Form 4) - Quantisnow
X4 Pharmaceuticals, Taiba to Distribute Xolremdi in Select Middle East Countries -February 19, 2025 at 10:56 am EST - Marketscreener.com
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries - Marketscreener.com
X4 Pharmaceuticals and Taiba Rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI®? in WHIM Syndrome in Select Middle East Countries - Marketscreener.com
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 22.6% in January - MarketBeat
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Yahoo Finance
X4 pharmaceuticals chief commercial officer Mark Baldry acquires $19,251 in stock By Investing.com - Investing.com South Africa
X4 pharmaceuticals chief commercial officer Mark Baldry acquires $19,251 in stock - Investing.com India
HC Wainwright Cuts Earnings Estimates for X4 Pharmaceuticals - MarketBeat
Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech
SG Americas Securities LLC Increases Stock Holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire
Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - News & Insights
FY2027 EPS Forecast for X4 Pharmaceuticals Cut by Analyst - Defense World
FY2028 Earnings Estimate for XFOR Issued By HC Wainwright - Defense World
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion - Business Wire
X4 Pharmaceuticals Inc (XFOR) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Is X4 Pharmaceuticals Inc (NASDAQ:XFOR) stock a better investment at this time? - US Post News
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals Inc [XFOR] Records 200-Day SMA of $0.7110 - Knox Daily
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia - Marketscreener.com
X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce - BioSpace
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services - PR Newswire
X4 lays off 30% of staff to focus on Xolremdi rollout - Fierce Biotech
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
X 4 Pharmaceuticals Inc (XFOR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
Nov 15 '24 |
Buy |
0.34 |
13,404 |
4,598 |
129,173 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
6.45%
1.23%
大文字化:
|
ボリューム (24 時間):